Charles River and Aitia Enter Strategic Agreement to Utilize Logica in Discovery Programs for Neurodegenerative Diseases and Oncology

Strategic partnership includes co-development of patient-derived xenograft (PDX) Digital Twins for in vivo oncology research Charles River to make an equity investment in Aitia as part of the agreement  WILMINGTON, Mass. & Somerville, Mass. – November 13, 2023: Charles River Laboratories International, Inc. (NYSE: CRL) and Aitia, a leader in the application of Causal AI and […]